Readout of Tropion-Lung01, testing the most advanced indication for datopotamab, could lead to a first-half US filing.
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.